Final cardiovascular risk Table 2. Final Cardiovascular LOW NOT LOW CV treatment related risk CV treatment related risk risk LOW Low Mild global CV patient risk NOT LOW Mild Severe global CV patient risk Baseline characteristics and treatments according to cardio-vascular risk Table 3. patient’s Variable Low Risk (n=18) Mild Risk (n=63) Total (n=81) P value Age (mean) 55.4 53.1 53.6 0.47 Hypertension 5 (27.7%) 13 (20.6%) 18 (22.2%) 0.83 PAS (mean) 123 123 123 0.89 Diabetes 0 2 (3.2%) 2 (2.5%) 0.44 Smoke 1 (5.6%) 7 (11.1%) 8 (9.8%) 0.46 Cho TOT (mean) 223 230 228 0.59 Cho HDL (mean) 58 60 59 0.59 BMI (mean) 23.8 24.1 24.0 0.70 CHT lines Neo-adjuvant (%) 1 (5.6%) 5 (7.9%) 6 (7%) Adjuvant (%) 15 (83.3%) 55 (87.3%) 70 (87%) 0.59 Other (%) 2 (11.1%) 3 (7.8%) 5 (6%) Cycles (>=6) 8 (44.5%) 49 (77.7%) 57 (70.4%) 0.41 Chemo T 9 (50%) 51 (81%) 60 (74%) 0.008 A 10 (55.6%) 58 (92.1%) 68 (83.9%) 0.0001 Herceptin 0 20 (31.7%) 20 (25%) 0.006 A +T 4 (22.2%) 47 (74.6%) 51 (62.9%) 0.0001
Table 2. Final cardiovascular risk Final Cardiovascular risk LOW CV treatment related risk NOT LOW CV treatment related risk LOW global CV patient risk Low Mild NOT LOW global CV patient risk Mild Severe Table 3. Baseline patient’s characteristics and treatments according to cardio-vascular risk Variable Low Risk (n=18) Mild Risk (n=63) Total (n=81) P value Age (mean) 55.4 53.1 53.6 0.47 Hypertension 5 (27.7%) 13 (20.6%) 18 (22.2%) 0.83 PAS (mean) 123 123 123 0.89 Diabetes 0 2 (3.2%) 2 (2.5%) 0.44 Smoke 1 (5.6%) 7 (11.1%) 8 (9.8%) 0.46 Cho TOT (mean) 223 230 228 0.59 Cho HDL (mean) 58 60 59 0.59 BMI (mean) 23.8 24.1 24.0 0.70 CHT lines Neo-adjuvant (%) Adjuvant (%) Other (%) 1 (5.6%) 15 (83.3%) 2 (11.1%) 5 (7.9%) 55 (87.3%) 3 (7.8%) 6 (7%) 70 (87%) 5 (6%) 0.59 Cycles (>=6) 8 (44.5%) 49 (77.7%) 57 (70.4%) 0.41 Chemo T A Herceptin A +T 9 (50%) 10 (55.6%) 0 4 (22.2%) 51 (81%) 58 (92.1%) 20 (31.7%) 47 (74.6%) 60 (74%) 68 (83.9%) 20 (25%) 51 (62.9%) 0.008 0.0001 0.006 0.0001